Apolipoprotein C-III-Reference-Cited by-同舟云学术

Apolipoprotein C-III

Published:2015-04 Issue:2 Volume:22 Page:119-125
ISSN:1752-296X
Container-title:Current Opinion in Endocrinology, Diabetes & Obesity
language:en
Short-container-title:

Author:

Kohan Alison B.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference80 articles.

1. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia.;Hobbs;Hum Mutat,1992

2. I. Reduction in incidence of coronary heart disease.;JAMA,1984

3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).;Lancet,1994

4. The 2013 American College of CardiologyAmerican Heart Association guidelines on treating blood cholesterol and assessing cardiovascular risk: a busy practitioners guide.;Gupta;Endocrinol Metab Clin North Am,2014

5. Lipid management to reduce cardiovascular risk: a new strategy is required.;Superko;Circulation,2008

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk;New England Journal of Medicine;2024-09-02

2. Derivation and external validation of mass spectrometry-based proteomic model using machine learning algorithms to predict plaque rupture in patients with acute coronary syndrome;Clinica Chimica Acta;2024-09

3. Targeting Apolipoprotein C-III for the Management of Severe Hypertriglyceridemia: Current Research and Future Directions;Cureus;2024-08-17

4. Impaired intestinal free fatty acid transport followed by chylomicron malformation, not pancreatic insufficiency, cause metabolic defects in cystic fibrosis;Journal of Lipid Research;2024-07

5. Advances in nucleic acid-targeted therapies for cardiovascular disease prevention;Cardiovascular Research;2024-07